TNSN00114A1 - Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents
Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenantInfo
- Publication number
- TNSN00114A1 TNSN00114A1 TNTNSN00114A TNSN00114A TNSN00114A1 TN SN00114 A1 TNSN00114 A1 TN SN00114A1 TN TNSN00114 A TNTNSN00114 A TN TNSN00114A TN SN00114 A TNSN00114 A TN SN00114A TN SN00114 A1 TNSN00114 A1 TN SN00114A1
- Authority
- TN
- Tunisia
- Prior art keywords
- cancer
- tetrahydrofuranne
- arylsulfonylamino
- carboxylic
- preparation
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 230000009033 hematopoietic malignancy Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940063683 taxotere Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- -1 vincristine Natural products 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
Abstract
L'INVENTION CONCERNE UN COMPOSE DE FORMULE I : DANS LAQUELLE R1, R2 ET Q REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR SA PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEURS D'ENZYMES, DANS LE TRAITEMENT DE DIVERSES MALADIES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13667799P | 1999-05-28 | 1999-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN00114A1 true TNSN00114A1 (fr) | 2002-05-30 |
Family
ID=22473882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN00114A TNSN00114A1 (fr) | 1999-05-28 | 2000-05-24 | Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6342521B1 (fr) |
| EP (1) | EP1181285B1 (fr) |
| JP (1) | JP3828748B2 (fr) |
| AT (1) | ATE251618T1 (fr) |
| AU (1) | AU4309800A (fr) |
| BR (1) | BR0011538A (fr) |
| CA (1) | CA2375513C (fr) |
| DE (1) | DE60005818T2 (fr) |
| DK (1) | DK1181285T3 (fr) |
| ES (1) | ES2203456T3 (fr) |
| GT (1) | GT200000084A (fr) |
| HN (1) | HN2000000052A (fr) |
| MA (1) | MA26737A1 (fr) |
| MX (1) | MXPA01012266A (fr) |
| PE (1) | PE20010204A1 (fr) |
| PT (1) | PT1181285E (fr) |
| TN (1) | TNSN00114A1 (fr) |
| UY (1) | UY26169A1 (fr) |
| WO (1) | WO2000073294A2 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| JP4343373B2 (ja) * | 2000-01-14 | 2009-10-14 | 富士フイルム株式会社 | 写真サービスシステム及びデジタルカメラ |
| NZ520656A (en) * | 2000-03-21 | 2004-05-28 | Procter & Gamble | Heterocyclic side chain containing metalloprotease inhibitors |
| IL151125A0 (en) | 2000-03-21 | 2003-04-10 | Procter & Gamble | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| JP2003528082A (ja) | 2000-03-21 | 2003-09-24 | ザ プロクター アンド ギャンブル カンパニー | ニフッ化酪酸メタロプロテアーゼ阻害物質 |
| US6548539B1 (en) * | 2001-03-05 | 2003-04-15 | Avalon Pharmaceuticals | Agents for regulation of colon cancer gene expression |
| GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| RU2291497C1 (ru) * | 2005-06-28 | 2007-01-10 | Институт биомедицинских исследований Владикавказского научного центра РАН и Правительства РСО-Алания (ИБМИ ВНЦ РАН) | Способ лечения рака молочной железы в эксперименте |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| CA2804173C (fr) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Inhibiteurs de nav1.7 de type sulfonamide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5663357A (en) * | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| ID22849A (id) * | 1997-01-23 | 1999-12-09 | Hoffmann La Roche | Penghambat-penghambat sulmafida-metaloprotease |
| IL131042A0 (en) * | 1997-02-03 | 2001-01-28 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU8858398A (en) * | 1997-07-10 | 1999-02-08 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
| AU746877B2 (en) * | 1997-07-31 | 2002-05-02 | Procter & Gamble Company, The | Acyclic metalloprotease inhibitors |
-
2000
- 2000-04-12 HN HN2000000052A patent/HN2000000052A/es unknown
- 2000-05-15 BR BR0011538-0A patent/BR0011538A/pt not_active IP Right Cessation
- 2000-05-15 AU AU43098/00A patent/AU4309800A/en not_active Abandoned
- 2000-05-15 AT AT00922821T patent/ATE251618T1/de not_active IP Right Cessation
- 2000-05-15 ES ES00922821T patent/ES2203456T3/es not_active Expired - Lifetime
- 2000-05-15 DK DK00922821T patent/DK1181285T3/da active
- 2000-05-15 DE DE60005818T patent/DE60005818T2/de not_active Expired - Fee Related
- 2000-05-15 MX MXPA01012266A patent/MXPA01012266A/es active IP Right Grant
- 2000-05-15 PT PT00922821T patent/PT1181285E/pt unknown
- 2000-05-15 JP JP2000621360A patent/JP3828748B2/ja not_active Expired - Fee Related
- 2000-05-15 EP EP00922821A patent/EP1181285B1/fr not_active Expired - Lifetime
- 2000-05-15 CA CA002375513A patent/CA2375513C/fr not_active Expired - Fee Related
- 2000-05-15 WO PCT/IB2000/000646 patent/WO2000073294A2/fr active IP Right Grant
- 2000-05-24 TN TNTNSN00114A patent/TNSN00114A1/fr unknown
- 2000-05-24 MA MA25987A patent/MA26737A1/fr unknown
- 2000-05-25 US US09/578,661 patent/US6342521B1/en not_active Expired - Fee Related
- 2000-05-26 GT GT200000084A patent/GT200000084A/es unknown
- 2000-05-26 UY UY26169A patent/UY26169A1/es not_active Application Discontinuation
- 2000-05-26 PE PE2000000510A patent/PE20010204A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU4309800A (en) | 2000-12-18 |
| DK1181285T3 (da) | 2004-01-26 |
| US6342521B1 (en) | 2002-01-29 |
| PE20010204A1 (es) | 2001-03-05 |
| DE60005818D1 (de) | 2003-11-13 |
| GT200000084A (es) | 2001-11-17 |
| BR0011538A (pt) | 2002-02-26 |
| DE60005818T2 (de) | 2004-05-06 |
| HN2000000052A (es) | 2001-02-02 |
| EP1181285A2 (fr) | 2002-02-27 |
| JP2003500484A (ja) | 2003-01-07 |
| WO2000073294A2 (fr) | 2000-12-07 |
| PT1181285E (pt) | 2004-01-30 |
| UY26169A1 (es) | 2000-12-29 |
| MXPA01012266A (es) | 2002-07-30 |
| ATE251618T1 (de) | 2003-10-15 |
| CA2375513A1 (fr) | 2000-12-07 |
| CA2375513C (fr) | 2006-11-28 |
| MA26737A1 (fr) | 2004-12-20 |
| JP3828748B2 (ja) | 2006-10-04 |
| EP1181285B1 (fr) | 2003-10-08 |
| ES2203456T3 (es) | 2004-04-16 |
| WO2000073294A3 (fr) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN99157A1 (fr) | Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| EA199900641A1 (ru) | Производные арилсульфонилгидроксамовой кислоты | |
| MY121754A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
| MA26737A1 (fr) | Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3-carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| AP2001002070A0 (en) | Hydroxy pipecolate hydroxamic acid derivatives as MMP Inhibitors. | |
| NO990821L (no) | Arylsulfonylamino-hydroksaminsyre-derivater | |
| NO20025792D0 (no) | Kinazolinderivater for behandling av tumorer | |
| BG106694A (en) | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | |
| TNSN00111A1 (fr) | Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| IT1169858B (it) | Complessi platino-diamminici, procedtimento per la loro prreparazione,procedimento per la preparazione di una compossizione medica contenente tali complessi platino-diamminici per il trattamento del cancro,nonche' composizione cosi' realizzata | |
| CA2392271A1 (fr) | Sulfonylheteroaryltriazoles comme agents anti-inflammatoires/analgesiques | |
| MA19952A1 (fr) | Nouveaux derives de la nitrosouree, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| FR2444036A1 (fr) | 2-phenylamino-imidazolines-(2) substituees, possedant des proprietes therapeutiques particulieres, procede pour leur preparation et composition pharmaceutiques les contenant | |
| EP2054398A4 (fr) | Nouveaux composés hétérocycliques contenant des atomes d'azote ou des sels acceptables de ceux-ci du point de vue pharmaceutique, procédé permettant de les préparer et composition pharmaceutique comprenant ceux-ci pour le traitement du cancer |